Chemistry and Cancer Program

跨学科的化学和癌症（CC）计划是唯一位于西蒙斯综合 癌症中心（SCCC）将基础生物学研究与新疗法的发现联系起来， 癌症的治疗。气候变化促进了许多方案内和方案间的合作， 这导致了对癌症生物学的新认识和具有高度临床应用性的药物发现。CC 结合了合成和药物化学家，分子和结构生物学家，生物化学家， 化学生物学家，药理学家和临床科学家发现，设计和优化药物样小 在癌症中调节生物途径的分子被解除调节。CC的发现平台由 一种跨学科和以化学为重点的癌症生物学方法将提供新途径的假设 在癌症预防和治疗方面的发现。CC计划由Jef De Brabander博士共同领导， Uttam Tambar博士，由来自校园七个部门的22名成员组成。的 CC科学计划有三个具体目标：（1）鉴定新型抗肿瘤药物的分子靶点。 癌症因子，（2）与人类癌症相关的调节途径的生物化学剖析，和（3） 干扰癌症相关信号通路的化学物质的结构设计。 CC计划的重点是加速在UT化学发现的持续翻译 西南医学中心（UTSW）和SCCC的临床，早期阶段的转化研究的启动， 以及中晚期临床前研究的许可。CC计划将继续优先研究 影响SCCC集水区流行的癌症的计划，如结直肠癌，肺癌，肾癌， 和肝癌。此外，CC计划还将促进跨计划和计划内 在三个具体目标方面开展合作并探索新项目。 CC计划的直接同行评审资金总额为520万美元，其中260万美元（51%）来自NCI。CC计划 自2014年以来，成员已撰写了253篇同行评审出版物，其中17%是项目内出版物， 40%是跨学科的，36%是在影响因子≥ 10的期刊上。

The interdisciplinary Chemistry and Cancer (CC) Program is uniquely situated in Simmons Comprehensive Cancer Center (SCCC) to bridge fundamental biology research with the discovery of novel therapies for the treatment of cancer. CC has facilitated numerous intraprogrammatic and interprogrammatic collaborations, which have resulted in new insights into cancer biology and drug discovery of high clinical applicability. CC combines the expertise of synthetic and medicinal chemists, molecular and structural biologists, biochemists, chemical biologists, pharmacologists, and clinician scientists to discover, design, and optimize drug-like small molecules that regulate biological pathways deregulated in cancer. CC’s discovery platform is guided by the hypothesis that an interdisciplinary and chemically focused approach to cancer biology will provide new avenues for discovery in cancer prevention and treatment. The CC Program is co-led by Jef De Brabander, PhD, and Uttam Tambar, PhD, and is composed of 22 members who are drawn from seven departments on campus. The CC Scientific Program is defined by three specific aims: (1) Identification of Molecular Targets of Novel Anti- Cancer Agents, (2) Biochemical Dissection of Regulatory Pathways Relevant to Human Cancer, and (3) Structure-Based Design of Chemicals that Perturb Cancer-Relevant Signaling Pathways. The CC Program focuses on acceleration of the continued translation of chemical discoveries made at the UT Southwestern Medical Center (UTSW) and SCCC to the clinic, the initiation of early-stage translational studies, and the licensing of mid- to late-stage preclinical studies. The CC Program will continue to prioritize research programs that impact cancers that are prevalent in the SCCC catchment area, such as colorectal, lung, kidney, and liver cancers. In addition, the CC Program will promote interprogrammatic and intraprogrammatic collaborations and explore new projects in the three specific aims. Total direct peer-reviewed funding to the CC Program is $5.2M, with $2.6M (51%) from the NCI. CC Program members have authored 253 peer-reviewed publications since 2014, of which 17% were intraprogrammatic, 40% interprogrammatic, and 36% were in journals with impact factors ≥ 10.